

Company Overview

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Validive® (clonidine HCl MBT), a Phase 2b/3 mucoadhesive buccal tablet for the prevention and treatment of radiation-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin (MNPR-201; formerly GPX-150), a proprietary Phase 1b clinical-stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; MNPR-101 RIT, a preclinical-stage radio-immunotherapeutic (RIT) for the treatment of advanced solid cancers and severe COVID-19; MNPR-101 (formerly huATN-658), a late stage preclinical humanized monoclonal antibody, which targets the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced cancers; and MNPR-202, a proprietary early-stage potent camsirubicin analog in various cancers.

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

Nov 12 2021, 8:00 AM EST

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma

Oct 27 2021, 8:05 AM EDT

Stock Overview

Symbol	MNPR
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

Management Team

Chandler D. Robinson, MD MBA MSc

Co-Founder, Chief Executive Officer and Board Member

Christopher M. Starr, PhD

Co-Founder and Executive Chairman of the Board

Andrew P. Mazar, PhD

Co-Founder and Executive Vice President, Research and Development

Chief Scientific Officer and Board Member

Kim R. Tsuchimoto

Chief Financial Officer, Secretary and Treasurer

Monopar Therapeutics Inc.

1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.